New Collaboration With Stevanato Group to Elevate mRNA Production With Nfinity Platform

Quantoom Biosciences recently announced a new collaboration with Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of promoting and democratizing access to cutting-edge mRNA production technologies worldwide. The focus of this collaboration lies in harnessing the potential of Quantoom’s revolutionary Nfinity Platform, a state-of-the-art, fully automated mRNA production platform, to contribute to the betterment of global health. This collaboration brings together the innovative capabilities of both industry leaders with a shared vision to enhance global health outcomes through advanced engineering and scientific solutions.

The Nfinity Platform comprises multiple systems, designed with a small footprint, seamless automation, and cost-effectiveness. Tailored to cater to the burgeoning demand for DNA and mRNA manufacturing and encapsulation, these systems are synergistically integrated with custom single-use consumables and ready-to-use reagent premixes. By combining their respective expertise, Quantoom and Stevanato Group will strive to cultivate a scalable optimized technology portfolio that would enable the economical production of mRNA on a global scale, thereby advancing the treatment landscape and improving global health.

“Our journey began less than 2 years ago with a vision to revolutionize mRNA production, and today, I am immensely proud of the strides we’ve made. The collaborative efforts poured into our Nfinity Platform have yielded an exceptional automated mRNA production solution. The vitality of this collaboration with Stevanato Group underscores the innovative spirit that drives us. Witnessing where the company stands today is not only exciting but a testament to the dedication and ingenuity of our team, as well as the meaningful partnerships we forge,” said José Castillo, Chief Executive Officer at Quantoom Biosciences.

“Stevanato Group has the potential to bring innovation to the mRNA field,” said Andrea Zambon, Corporate Business Development Director at Stevanato Group. “Our expertise and capabilities in primary packaging, equipment, and analytical services for biopharmaceutical manufacturing make Stevanato Group the natural partner for Quantoom. Together, our companies can enable customers to introduce new mRNA-based drugs into the market faster, benefiting the patients waiting for them.”